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Eighty-two patients who were t~eated at the Department of 
Dermatology, Innsbruck, Austna, from 1980 to 1987 for 
cutaneous manifestations of Lyme disease were subjected to a 
clinical follow-up investigation aimed at detecting derma to-
logic, neurologic, and int~rnal late co~plications of bo~r~­
liosis . Only 54 of these patlents had recelved adequate antibl-
otic treatment according to current standards. Also, their sera 
were investigated for the presence of immunoglobulin G 
(IgG) and IgM Borrelia burgdorferi a~tibodies by an in?irect 
immunofluorescence assay, three dlfferent enzyme-lmked 
immunosorbent assays, and immunoblotting. As a control, 
the sera of 126 healthy blood donors were investigated with 
the same assays. Results showed no unambiguous clinical late 
complications of Lyme borreliosis, even in inadequately 
treated or untreated patients. Seropositivity varied considera-
bly according to the assay used; the indirect immunofluores-
F ollowing the pioneering studies of Steere et al [1] on Lyme borreliosis in 1975, rapid progress led to the iden-tification of Borrelia burgdorferi as the causative agent [2], an understanding of the epidemiology and mode of transmission [3], development of serodiagnostic tests [4] , 
and the concept o~ B. burgdor{eri i.n~ecti~n as a complex systemic 
disease that compnses severaf entities hitherto regarded as unre-
lated. Finally, generally accepted therapeutic guidelines were rec-
ommended in 1985 [5,6]. 
Lyme borreliosis develops ill two [7] or three [8] consecutive 
stages. Early infection (stage I) is characterized by erythema chroni-
cum migrans (ECM), regional lymphadenopathy, and minor con-
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cence assay yielded the highest scores. The proportion of 
ser~positiv~ results (immunofluorescence assay) was 59% in 
patlents wlth erythema chronicum migrans, 69% in those 
with lymphocytoma cutis, and 100% in those with acroder-
matitis chronica atrophicans (overall 63%); in contrast, only 
31 % o~ ~he blood donor control group were found to be 
seropoSltive. Seropositivity did not correlate with adequacy 
of treat~l1ent, int~rval between onset of symptoms and treat-
ment, .time span sl?-ce t!eatment, age of patients, and presence 
of antmuclear antibodles. Immunoblot pattern showed high 
incidence of antibodies against the 29/31-kD (outer surface 
proteins.OspA and OspB) and.55/58-kD antigens in general 
and agamst. ~he 41-~D protem (flagellin) in patients with 
acrodermatltls chr011lca atrophicans only. ] Invest Dermatol 
100:103-109,1993 
stitutional sym~toms . Wi~hin we~ks, the infection may spread 
(stage II), resultmg m multiple malllfestations of the skin, nervous, 
or musculoskeletal ~ystems, or a combination of all of these [9]. 
Studies from the Ulllted States report a 15 -20% incidence of neuro-
logic mani~estations, ~p to S% cardiac involvement [S], and joint 
symptoms m up to SO Yo [9]. In Europe, some patients develop lym-
phocytoma cutis (Le) , a nodular pseudolymphoma most commonly 
located on the ear lobeand the mpple [10] . The clinical spectrum of 
late (s~age III~ :n~ectlon appears to be geographically variable. 
Chromc arthntls IS more often reported in the United States 
[11,1 2], whereas skin manifestations, such as acrodermatitis chron-
~ca atrophicans (ACA) and/or sclerod~rma-like lesions predominate 
m Europe. Late symptoms of the penpheral nervous system (inter-
mittent distal J?aresthesia or radicular pain) and central nervous sys-
tem (progreSSIve encepha.lomyehtl~ [13] or subacute encephalitis 
[14]) are rare but have attamed c0l1Slderabie public attention. In the 
United States, even dementia [15] and symptoms such as loss of 
memory, somnolence, and behaviorial changes have been attributed 
to B. btlrgdorferi as possible late neurologic abnormalities [16J. 
A~though skI.n l.eslOns of Lyme borreliosis are known to respond 
readily to antlbl~tlc treatment, infection may obviously persist in a 
laten.t form ~esplte. adequate therapy, giving rise to late neurologic 
or JOll1t mamfestatlons; data 011 the frequency of this are strikingly 
discrepant [9,17-23]. 
Immunoglobulin M (IgM) antibodies directed against a 41-kD 
polypeptide subunit of the flagellum [24] are the first to appear after 
3 - 6 weeks [10,25,26], often associated with serum IgM elevation 
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[27], circulating immu~e co~~l~xes [~8], ~heumatoid factor [2~], 
and antinuclear and anticardlOhpm antibodIes [30]. After a peak m 
the sixth week, IgM gradually declines but may also persist, p.arti~u­
lady if neurologic or joint sympto~s develop P1]. IgG antIbodIes 
appear within 6 weeks, most often dlrect~d agamst.t~e 31-,. 34-, and 
66-kD outer surface proteins. Patients wIth chromc mfectlon often 
develop antibodies against additional borreliayroteins [10,25,26]; 
despite several reports that indicat~ a staged I.mmune response. to 
certain proteins (see [32]), no defimte correlation. between specIfic 
patterns of disease and specific Western blot findmg~ has yet bee.n 
detected. In untreated individuals, the IgG response mcludes anti-
bodies against a variety of B. burgdorjeri proteins but only rarely 
against the major outer surface protems OspA (31 kD) and OspB 
(34 kD; strain B29 31 kI?) [33]. It has rece~t1y been shown i~ sev~re 
combined immunodeficIency (SCID) mIce that only antIbodIes 
against OspA can prevent experimental infection [33]. 
The effects of therapy on the long-term serologic status are 
largely unknown. Neumann et al [17] reported a re~~rs~on to nega-
tivity between 2 weeks and up to 4 mon~hs afte~ peru~lllm treatme~t 
in ECM patients. In stage ll.neu~ologl.c marufestatlo~s, IgG. a.n~l­
body titers declin.ed more rapIdly 111 patients t.reated WIth p~mcII.hn 
than in those Without treatment [19]. PerSIStence of antibodies, 
however, particularly ofIgM, against the 41-kD protein ins known 
to occur in patients with prolonged illness [28] and may indicate 
persistent infection [19]: According to Craf~ et al [10], .disease pro-
gression is associated WIth a gradual expansion of the Immune re-
sponse to di~eren~ borrelia proteins reg~rd.less of the pr~vailing 
clinical mamfestatlOns and despIte antIbIOtiC therapy dunng the 
early phase of infection. 
In Europe, ECM, LC, and ACA had been appreciated as rather 
harmless but not infrequent skin disorders for over 60 years [34]. 
They were thought to be caused by an unknown infectious agent 
and therefore have been empirically treated with penicillin or other 
antibiotics since the late 1940s [35-37]. Treatment regimens dif-
fered considerably and, according to present-day standards, were 
often inadequate [6]. Resolution of the skin lesions was obviously 
achieved in most cases [35 - 37], but it is unclear whether the pa-
tients so treated were at an increased risk for latent infection and 
systemic manifestations later ?n. . . 
In this study, we retrospectively exammed 82 patIents who were 
treated in the Department of Dermatology, Innsbruck, for cutane-
ous Lyme borreliosis in the early 1980s to compare incidence and 
type of late complications and the serologic status between those 
treated adequately and those treated inadequately according to 
present-day standards. Their serolol?ic .st~tus was also compared 
with that of a group of 126 healthy mdlVlduals. 
MATERIALS AND METHODS 
Patients This study includes 82 patients who were treated for 
cutaneous manifestations of Lyme borreliosis (ECM, n = 63; LC, 
n = 13; and ACA, n = 6) from 1980 to 1987 at the Department of 
Dermatology, Innsbruck. All patients were subjected to extensive 
clinical and serologic follow-up investigations aimed at detecting 
signs of persistent disease activity or late complications. Diagnoses 
were taken from the patients' files, except in cases ofLC, which, in 
view of its similarity to other cutaneous pseudolymphomas, were 
re-evaluated according to histology, clinical photographs, and re-
sponse to antibiotic treatment. 
Case Histories The following information was obtained from 
each patient's file and personal interviews taken according to a writ-
ten questionnaire: date and type of skin lesions; interval between 
development of skin lesions and onset of treatment; type of antibi-
otic administered, regimen used, and compliance with therapy; in-
cidence and type of consequent infectious diseases and type of antibi-
otic regimen then performed; any other consequent illnesses, 
particu larly of neur~logic, "rheumatic," or cardiac ~isor~ers; and 
dates of tick bites pnor to the development of the skl11 leSIons and 
later on. 
Type and Adequacy of Treatment The following antibiotic 
regimens, performed between 1980 and 1987, were qualified as 
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"adequate" for Lyme borreliosis according to current treatment 
standards [6]: ECM and LC, tetracycline 250 mg four times a day, 
minocycline or doxycycline 100 mg twice a day, penicillin V 
1000 mg three times a day, or erythromycin 250 mg four times a 
day, each for at least 10 d; ACA, penicillin G 10 million U twice a 
day for at least 10 d, benzathine penicillin 2.4 million U /week for 
at least 3 weeks; doxycycline 100 mg twice a day for at least 30 days, 
and ceftriaxon 2 g/day for at least 14 d. 
Clinical Investigations All patients were subjected to thorough 
physical, dermatologic, and neurologic examinations. The follow-
ing laboratory tests were performed: blood sedimentation rate, 
complete blood count, serum electrophoresis, liver function tests, 
electrolytes and rheumatoid factor, electrocardiography, electromy-
ography, and nerve conductance velocity. If indicated, spine X-ray, 
computerized tomography, and examination of spinal fluid were 
also performed. 
Serologic Tests Results of available serodiagnostic tools for the 
diagnosis of Lyme borreliosis are known to vary from test to test; in 
this study, therefore, several immunoassays were performed. Only 
two of these (Medor) use the European strain B 29 as antigen; the 
Virotech assays have only limited value because they use B. burgdor-
Jeri flagella - associated antigens. The Western blot was used for its 
high sensitivity and specificity and should provide information on 
individual differences of the antibody response to the various anti-
gens of B. burgdorferi. 
Patient sera and control sera from 126 healthy blood donors from 
the Innsbruck area were subjected to the following B. bllrgdorferi 
antibody assays, which were each carried out according to the direc-
tions of the manufacturer. 
Indirect Immunofluorescence Assay (IIFA): IIFA (BIOS, Grafelfing, 
Munich, Germany), which uses B. burgdorJeri strain B 31 as antigen, 
was performed to determine IgG antibodies. Sera with titers greater 
than 1: 256 were considered positive. Positive sera were further 
diluted and tested until negative. 
Enzyme-Linked lmmunosorbent Assay (ELISA): 1) Virotech ELISA 
(Virotech Systemdiagnostica, Riisselsheim, Germany), which uses a 
recombinant flagella-associated protein (B . bllrgdorferi strain B 31) as 
antigen, was performed for IgG and IgM antibodies. Sera with an 
optical density reading greater than 0.3 (IgG) and greater than 0.35 
(IgM) were considered positive. IgM antibodies were not deter-
mined in the sera of the blood donors. 2) Medor ELISA (Medor 
Laboratorien fur Biochemie und Klinische Chemie, Herrsching, 
Munich, Germany) was performed for IgG and total Ig (y, /1, ex, K, 
A). This test uses the European strain B 29 as antigen. Interpretation 
was based on the optical density of the low-titered positive control: 
sera with an absorbance of 10% greater than that of the low-titered 
positive control serum were considered positive. Sera with readings 
near the cutoff point (± 10%) were tested a second time and consid-
ered positive only if their absorbance was greater than that of the 
low-titered positive control serum. 3) Riihm ELISA (Rohm 
Pharma, Darmstadt, Germany), which uses an extract of strain B 31 
as antigen, was performed for IgG. Sera were considered positive if 
their absorbance exceeded 0.35. 
ImmutlOblot Assay: Immunoblot assay, which uses B. burgdorJeri 
strain B 29 as antigen, was developed in the laboratories of one of us 
(GSt) and is now commercially available (Medoblot; Medor Labora-
torien). With this test, both IgG and total Ig (see above) were 
determined. A positive serum reactive with B. burgdorferi proteins 
with molecular weights of14, 17, 19,22,27,29/31,37,41,43/47, 
55/58,60,66, 83 kD and a negative serum reactive with none of 
these proteins were used as controls. The molecular mass standard 
from Sigma Chemical Co. (St. Louis, MO) (Dalton mark VII-L and 
Escherichia coli .a-galactosidase) was used for assessing apparent mo-
lecular weights. Bands used for diagnosis included the 17, 22, 29/ 
31,41, and 55/58-kD proteins. Patient sera were considered posi-
tive if strongly reactive at a dilution of 1 : 500 with at least one of 
t~ese proteins. No differences were observed at lower serum dilu-
ttons (e.g., 1: 100). 
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Table I. Correlation of Serologic Data and Adequacy of Treatment 
Treatment (n) IIFA Virotech 
Erythema chronicum 
migrans 
27 (66.0%) 19 (43.2%) Adequate (45) 
Inadequate (12) 5 (41.7%) 4 (25.0%) 
No treatment (6) 5 (83.3%) 3 (50.0%) 
All patients (63) 37 (58.7%) 26 (41.9%) 
Lymphocytoma cutis 
5 (62.5%) 5 (62.5%) Adequate (8) 
Inadequate (1) 1 (100%) 
No treatment (4) 3 (75.0%) 3 (75.0%) 
All patients (13) 9 (69.2%) 8 (61.5%) 
Acrodermatitis 
chronica 
atrophicans 
1 (100%) 1 (100%) Adequate (1) 
Inadequate (5) 5 (100%) 5 (100%) 
No treatment (0) 
All patients (6) 6 (100%) 6 (100%) 
All borrelioses 
Adequate (54) 33 (61.1 %) 25 (47.2%) 
Inadequate (18) 11 (61.1%) 8 (44.0%) 
No treatment (10) 8 (80.0%) 6 (60.0%) 
All patients (82) 52 (63.4%) 39 (47.6%) 
Blood donors 126 39 (31.0%) 42 (33.3%) 
All sera were further tested for the presence of antinuclear anti-
bodies (ANA) (Hep2 cells; Kallestad Diagnostics, TX) and sub-
jected to the microhemagglutinine Treponema pal/idum test (Fujire-
bio, Inc., Tokyo, Japan). 
Correlation of B . burgaorferi Serology with Clinical Data 
Calculations were based on the results of the IIFA. 
Statistical Analysis Data were analyzed by the chi-square test. 
RESULTS 
Analysis of Case Histories 
Tick Bites: On average, 63% of the patients with cutaneous borre-
liosis remembered one or several tick bites prior to the development 
of the skin lesion, 80% lived or frequently hiked in wooded areas, 
and 60% remembered one or more additional tick bites after treat-
ment. The interval between tick bite and first clinical symptoms was 
given as 4 weeks in ECM (range 3 d-3 months) and 5.5 weeks in 
LC (range 2 weeks-2 months). The interval between tick bite and 
onset of antibiotic treatment was 6 weeks in patients with ECM, 7.5 
weeks in patients with LC, and 9 months in the single patient with 
ACA who remembered a tick bite. 
Interval Between O"set of Ski" Symptoms a"d Treatment: This was 4 d 
on average in patients with ECM and 1 week for LC in those 
patients who remembered a tick bite at the site of their lesions. 
Patients who did not remember a tick bite presented much later for 
therapy (ECM, 6.5 weeks, range 1 d to 6 months; LC, 3 months, 
range 3 weeks - 6 months; ACA, 7 months, range 1 month - 1 year). 
No patient with LC or ACA remembered an ECM-like lesion prior 
to his or her symptoms. 
Time Spatl Since Antibiotic Treatment: Treatment had been per-
formed 4 (± 2.2) years before this study was carried out in patients 
with ECM, 4.2 (± 0.1) years in patients with LC, and 4.7 (± 1.2) 
years in patients with ACA. 
Adequacy of Treatment Performed: Only 54 of 82 (65.8%) patients 
were considered to have been adequately treated (Table I). Ten 
patients (12.2%) had received no antibiotic therapy at all, most often 
because of poor patient compliance. In 18 patients (22%), the doses 
were too low or were administered for too short a time. 
ELISA 
Immunoblot 
Rohm Medor Assay 
2 (4.5%) 26 (59.1%) 9 (20.0%) 
2 (16.7%) 4 (33.3%) 2 (16.7%) 
3 (50.0%) 1 (16.7%) 4 (66.7%) 
5 (8.1%) 33 (53.2%) 15 (24.2%) 
1 (12.5%) 5 (62.5%) 4 (50.0%) 
1 (100%) 
1 (25.0%) 3 (75.0%) 2 (50.0%) 
2 (15.4%) 9 (69.2%) 6 (46.2%) 
1 (100%) 1 (100%) 
3 (60.0%) 5 (100%) 5 (100%) 
3 (50%) 6 (100%) 6 (100%) 
3 (5.7%) 31 (58.5%) 14 (36.4%) 5 (27.8%) 10 (55.6%) 7 (38.1 %) 
2 (20.0%) 6 (60.0%) 6 (60.0%) 
10 (12.2%) 47 (57.3%) 27 (32.9%) 21 (16.7%) 49 (38.9%) 11 (9.5%) 
Lat~r Antibiotic Treatment for UI/related Conditions: Twenty-seven 
patients (ECM, n = 22; LC, n = 5), including nine who had been 
"inadequa~ely" treated, repo~ted additional antibiotic therapy at 
later ~ccasl?ns for unre~ated disorders, such as tonsillitis and urinary 
tract infectIOns; according to the history given, most of these later 
courses were not "adequate" for the treatment ofborreliosis either. 
Clinical Follow-Up Data 
Skin Mal/ifestations: . None of the patients previously treated for 
ECM and LC had skin leSIOns related to borreliosis either at the site 
of the o~i~in~llesion?r on the rest of the body. On~ patient with LC 
(no antibIOtiCS; prevIOus ther~py by excision in 1984) had had a 
relapse at t~e same location; .tlllS patient was proved seronegative by 
all serologiC tests. Three p~t1ents t~eated for ACA (Table II, patients 
~ 16, 1~2, ~nd 126) had. reSidual skm atrophy without signs of activ-
Ity. Skin disorders obVIOusly unrelated to borreliosis were detected 
in 14 patients (ros~cea, hypomelanosis guttata, vitiligo, Dupuy-
tren's contracture, hchen planus, pityriasis versicolor). 
N eurologiC E~aminati~tI : A wide spectrum of neurologic symptoms 
were found m 34 patlen~s (4 ~ %), most of these obviously attributa-
ble to unrelated underlymg disorders (Table III) . The incidence was 
lowest (35%) in the ECM group and highest (83%) in the ACA 
group. ,!here was a trend b~t no significant correlation between age 
a~d inCidence ?f ~eurologlC symptoms (the mean age of patients 
~Ith neurologiC signs was 57 years; of those without neurologic 
Signs, the. mean age was 37 years; p < 0.25). Fourteen patients with 
neurologiC symptoms were seronegative. 
Six of the patients with ECM displayed neurologic symptoms 
that were no~ ~xplainable by unrelated causes. Only three of these 
were seropositive and thus possibly attributable to borreliosis (one 
case each of carpal tunnel syndrome, unclear focal cerebral symp-
toms, and polyneuropathy) . Treatment had been adequate in all 
three patients. 
In the LC group, three patients presented with neurologic symp-
toms not clearly due to unrelated causes. One 65-year-old patient 
(Ta?~e II, pat!ent 70) had frontal lobe encephalopathy; he was sero-
posItive despite adequate treatment. Further neurologic investiga-
tions were refused, but it was thought that his symptoms were 
probably not due to B. burgdorferi infection for the localized type of 
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Table II. Immunoblot Patterns and Adequacy of Treatment 
Time Since Interval Between Protein Bands (kD)b 
Diagnosis Patient Treatment Skin Symptoms and 
Number Therapy (years) Treatment (days) 17 22 27 29/31 37 41 43/47 55/58 66 
Erythema chronicum 
migrans 
Adequate 8 0 X X 13 
18 Adequate 5 4 X X X 
19 Inadequate 2 21 X X 
20 None 3' X 
27 Adequate 3 30 X X 
30 Adequate 2 0 X X X 
38 None 7' X X 
39 None 7' X X 
42 Adequate 5 120 X 
44 Inadequate 3 1 X X X X 
47 Adequate 2 0 X X X 
52 None 8' X X X 
54 Adequate 3 21 X X X X X 
61 Adequate 1 7 X X 
85 Adequate 1 14 X X 
Lymphocytoma cutis 
Adequate 4 35 X X X 65 
66 Adequate 5 30 X X X 
70 Adequate 3 60 X X X X X X 
72 None 4' X X X X 
84 None 4' X X X 
86 Adequate 4 X X X 
Acrodermatitis chronica 
atrophicans 
Inadequate 5 270 X X X 116 
119 Inadequate 3 270 X X X X X X X 
122 Adequate 4 180 X X X X X 
124 Inadequate 6 365 X X X 
125 Inadequate 6 30 X X X 
126 Inadequate 4 270 X X X 
Blood donors 
303 X X X X 
341 X X X X 
353 X X X 
359 X X X X 
383 X X X X 
385 X 
390 X 
397 X X 
400 X X X X X 
405 X X 
416 X X 
6 Time since onset of skin symptoms. 
b The 22-kD band may contain the protoplasmic cylinder protein; the 29/31-kD band contains both OspA and OspB; the 37-kD band may correspond to a 39-kD band described 
by Ma et al [32]. or this latter band was not resolved underthe clectrophoreticconditions used. The 41-kD band is the f1agellin protein; the 55/58-kD region may contain the common 
antigen and. possibly. the 60-kD heat shock protein as well (for references. sec [32]) . 
the encephalopathy. Two patients had localized peripheral neuropa-
thies; both were seropositive despite adequate treatment. 
With the possible exception of one patient with carpal tunnel 
syndrome (Table II, patient 116), which was possibly a sequela of 
her ACA on both arms, neurologic symptoms of the patients with 
ACA were clearly attributable to degenerative spine disease or to age 
(74- 78 years). The only young patient in this group (patient 119, 
23 years old) had no neurologic symptoms. All patients in this group 
were seropositive in most or all assays (see below). 
Arthralgias: Arthralgias were reported or found in three patients; 
one of them (ECM, adequate therapy) had ANA - positive, rheuma-
toid factor- negative primary chronic polyarthritis; another (LC, 
adequate therapy) had meniscall~sions da~ing back years before his 
LC. Both pat ients were seronegative. A tlmd (ECM, adequate ther-
apy) had chondropathia patellae; she was seropositive. 
Electrocardiograms: . Electrocar~iograms revealed first-degree atrio-
ventricular blocks 111 three patients. Tim was obVIOusly related to 
hypertensive cardiomyopathy in one patient (ECM, adequate treat-
ment, negative serology). In two other seropositive patients (Table 
II, patient 47, ECM, and patient 124, ACA), atrioventricular block 
was more likely to be due to their age (78 and 82 years, respectively) 
than to borreliosis. 
Laboratory Tests: Laboratory test results were within the range of 
normal in most cases. Elevated serum lipids in five patients, slightly 
elevated liver transaminases in six patients, and benign paraprotein-
emia in one patient were clearly attributable to unrelated conditions 
(diabetes, chronic hepatitis, alcoholism, etc.). 
Serologic Data As expected, the results of B. burgdorJeri serology 
(IgG antibodies) varied considerably with the test methods used 
(Table I), IIFA consistently yielding the highest seropositivity rates, 
Rohm ELISA the lowest. IIFA and Medor ELISA displayed a high 
level of correlation. Incidence of seropositivity was higher (al-
though statistically not significant) in patients with LC than those 
with ECM. Patients with ACA were 100% seropositive in all assays 
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Table 1lI. Neurologic Symptoms in Patient Groups and Most 
Likely Cause 
IIFa 
Symptom (n) Most Likely Cause Seropositive 
Erythema chronicum migrans 
(n = 22/63) 
Vertebrostenosis 3/0 Radicular symptoms (6) 
Disk herniation 1/1 
U ncarthrosis 1/0 
Cervical syndrome 1/0 
Polyneuropathy (6) Parkinsonism 1/0 
Herpes zoster 1/0 
Hyperthyreosis 1/0 
Alcoholism 2/2 
None 1/1 
Encephalopathy (7) Alcoholism 2/1 
Multiple sclerosis 1/1 
M. parkinsonism 1/1 
Old age (> 80 years) 1/1 
None 2/1 
Myopathy (1) None 1/0 
Carpal tunnel syndrome (2) None 2/1 
Lymphocytoma cutis (n = 7/13)" 
Cervical syndrome 1/0 Radicular symptoms (2) 
Disk herniation 1/0 
Polyneuropathy (1) Old age «80 years) 1/1 
Encephalopathy (2) Old age 1/1 
None l/l b 
Distal neuropathy (3) Alcoholism 1/0 
None 2/2 
Strabism (1) Congenital 1/1 
Acrodermatitis chronica atroph-
icans (n = 5/6)" 
Vertebrostenosis 1/1 Radicular symptoms (1) 
Encephalopathy (3) Old age 3/3 
Polyneuropathy (3) Old age 3/3 
Carpal tunnel syndrome (1) None 1/1 
• Some patients exhibited more than one neurologic symptom. 
I Patient rejected further examinations. 
except Rohm ELISA (50%). It was thus fou~~ t.hat the ~ohm ELISA 
is very specific but of inadequately low. sensitiVity. The Immu~~b!ot 
was found to be both specific and sensitive, although the sensltlVlty 
of the Medor ELISA is higher and still accurate; the latter result may 
be due to the fact that antibodies to conformational epitopes are 
detectable only in the ELISA (GSt, unpublished data). . . 
Because it is well established that not all B. burgdorferr-mfected 
individuals undergo seroconversion [38], the percentage of serop?-
sitive individuals was high not only in the patients (63%) but also m 
the healthy blood donors (31%); it is noteworthy. that the ~ate of 
seropositivity was significantly higher in the patient than m the 
control group (p < 0.005). 
Anti-Borrelia-Flagella IgM Antibodies: Anti-.Borrelia-fla~ella I~M 
antibodies (Virotech ELISA; IgM) were found m three patients. with 
ECM, one with LC, and none with ACA. All also had IgG antibod-
ies by one or more assay methods, but only one (Table ~I, patient 39) 
was positive according to the immunoblot. RheumatOid factors a~d 
ANA were negative, except in one patient with ECM (1: 40; partic-
ular pattern) . Treatment had been performed less than 7 years prior 
to follow-up in all patients but one (ECM, 'patie~t 39). Treat~ent 
was inadequate or not performed in one patie~t with ECM (patl~nt 
39) and one with LC, respectively. One patient remembered tick 
bites after therapy. 
Syphilis Serology: Only one patient with ECM :vho had had s~c­
ond-stage syphilis in 1946 was positive by the mlcrohemag~lutl.n­
ine Treponima pallidium test; this patient also had IgG. antibodies 
against B. burgdorferi by the IIFA (1 : 512) but was negative accord-
ing to all other tests. 
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AntitJuc/ear Antibodies: Twenty-four (29%) of the 82 patients had 
ANA (ECM, n = 17; LC, n = 4; ACA, n = 3); four of them (ECM) 
had titers greater than 1: 80. The ANA pattern was speckled in 14 
patients (ECM, n = 13; LC, n = I), nucleolar in three (ECM, n = 
2; LC, n = 1), and homogenous in seven (ECM, n = 2; LC, n = 2; 
ACA, n = 3). No correlation between age and incidence of ANA 
was found. The incidence of ANA was approximately equal be-
tween male and female patients (24.1 % versus 29.7%). 
Correlation of Serology and Clinical Data 
Adeq.uate Versus Inadequate Treatment: No statistically significant 
differences were found with regard to the rates of seropositive pa-
tients (IgG) among the "adequately" treated, "inadequately" 
treated, and "no treatment" groups in all types of cutaneous borre-
liosis and for all assays performed (Table I). There was a trend, 
however, for both higher incidence of seropositivity and higher 
titers in the "no treatment" group, whereas few differences were 
found between "inadequately" and "adequately" treated patients. 
Time of Treatment: Patients with ECM and LC treated early 
(within 4 weeks of first clinical symptoms) had comparable rates of 
seropositivity (54% versus 57%) but tended to have lower titers of 
B. burgdorferi IgG antibodies according to all serologic assays com-
pared with those treated later (later than 4 weeks) or not at all; 
however, these differences were not statistically significant (p < 
0.25). 
Time Span Since Treatment: Seropositivity was slightly lower (al-
though statistically not significant) among patients with EM and 
LC treated 6 years or longer before this study was carried out than 
among those treated less than 6 years ago (53.8% versus 64%). 
Patient Age: No correlation with incidence or titer of B. burgdorferi 
antibodies was found in all assays. 
Correlation of Immunoblot Pattern to Clinical Data The 
Western blot assay is considered the most reliable technique and 
also provides data about the antibody response to the various anti-
gens of B. burgdorferi. Sera were investigated for total immunoglobu-
lins and for IgG, but no differences in the banding patterns were 
found. 
Positive sera from both patients and healthy blood donors almost 
invariably contained antibodies against the 55/58-kD and, slightly 
less frequently, the 29/31-kD proteins. Only the sera from patients 
had antibodies a.gainst the 27-kD protein; antibodies against the 
43/47-kD protems.were found more frequently in patients than in 
blood donors. Antl-37-kD proteins and anti-66-kD antibodies 
were infrequent but occurred only in patient sera. No correlation 
was found between time or adequacy of treatment and heterogene-
ity of antibodies against different B. burgdorferi proteins. 
ECM: The six patients with the anti-41-kD protein antibodies 
shared the shortest interval between onset of symptoms and treat-
ment (mean < 7 d); four of these (Table II, patients 30, 54, 61, and 
85) also had relatively short time spans since treatment (mean 1.75 
years). Other patients with short intervals since treatment (patients 
19,20,27,44, and 47), however, lacked anti-41-kD antibodies. 
Only one of these (patient 44) was inadequately treated. The occur-
rence of anti-41-kD antibodies did not correlate with a history of 
multiple tick bites. Anti-43/47-kD antibodies were found in four 
(patients 13, 18, 27, and 47) of five patients with short intervals 
between onset of symptoms and treatment (mean < 5 d). 
LC: Patients with anti-41-kD antibodies (Table II, patients 65, 
70, and 72) had a relatively short time span since treatment (mean 
3.5 years). The patient (patient 70) with the highest number of 
antibodies against different proteins had a short time interval be-
tween onset of symptoms and treatment (6 weeks), adequate ther-
apy, and a short time span since treatment. 
ACA: All patients had antibodies against 43/47- and 55/58-kD 
proteins. One (patient 119) had antibodies against multiple pro-
teins; he was the youngest of this group and had a history of multi-
108 PLORER ET AL 
pie tick bites, no adequate therapy, and a relatively short time span 
since treatment (3 years); this latter feature was shared with the two 
other patients (patients 122 and 126) with anti-41-kD antibodies 
(4 years). The remaining three patients had no anti - 41-kD antibod-
ies but fairly long time spans since treatment (mean < 5.7 years). 
The three patients (patients 124- 126) lacking anti - 29 /31-kD anti-
bodies had the longest intervals between onset of skin symptoms 
and treatment (9 - 12 months) and the longest time span since treat-
ment (6 years). 
DISCUSSION 
Retrospective analysis of patients with cutaneous Lyme borreliosis 
in the early 1980s reveals the surprising fact that 12% had received 
no treatment at all, and 22% had been treated inadequately. Never-
theless, none of the patients had dermatologic, neurologic, or other 
clinical symptoms that could be unambiguously interpreted as late 
complications of B. burgdorferi infection (except skin atrophy as 
sequela of ACA in three patients). Moreover, no significant correla-
tion between quality of treatment and present serologic status was 
found. 
These findings contrast sharply with published data. In the 
United States, Steere et af J9] observe? joint manifestations ranging 
from intermittent arthntlS to chroniC synovitis in 80% of 55 pa-
tients followed for 6 years. In Germany - an endemic area compara-
ble to our own-Weber et af [18] found arthralgias and neurologic 
symptoms in 28 of9~ ~atients with ECM in a 20-month follow-up 
despite adequate antibIOtic treatment. Asbrink et af [39] reported 
Lyme meningitis with facial palsy in two of 16 untreated ECM 
patients within 5 mo~ths after ?iagnosis. As the only exception, 
pfister et af found no differences 111 outcome in patients with Bann-
warth's meningoradiculitis treated with penicillin and others who 
received no treatmel1t [19]' 
One explanati~n for ~he .absence of late complications in our 
series is a more stnct applicatIOn of specificity criteria: in contrast to 
prevIous stu~le~ [18,40), symptoms were considered attributable to 
Lyme borrelIoSIS only If other more plausible etiologies were not 
demonstrable. Thus, all neurologic, joint, and cardiac symptoms 
obviously caused by accompanying disorders were excluded. We 
belie,:e that overdiagnosis may at least be in part responsible for the 
seemmg plethora of symptoms currently attributed to Lyme borre-
liosis; as a consequence, large numbers of patients receive antibiotic 
treatment for nonsp~c.ific symptoms, as demonstrated by Frank et 
af. * Low~r pathogemclty of European Borrelia strains is an unlikely 
explanatIOn, because high rates of late complications have been 
reported not only from the United States but also from Germany 
[12,13]. 
Another explanation addr~sses the fact that only patients who had 
presented With dermatologlc manifestations of Lyme borreliosis 
were included in ~)Ur study. El?idemi?logic evidence suggests that 
80% of pa~lents With neur~loglc manifestations of Lyme borreliosis 
have no history of ECM; In contr~st, on.ly 15% - 20% of patients 
With. ECM. develop neurologiC mal1lfestatlons [41,42]' Primary skin 
mal1lfestatlons may thus represent a marker of good prognosis. 
Furthermore, Imm~no~lot pa~terns from our patients showed a 
high mCidence of antibodies agamst the 29/31-kD protein, which 
contains OspA and OspB. Antibo.dies against OspA have recently 
bee.n shown ~apable of :onveymg Immun~ty to experimental borre-
lia 1I1fectIon1l1 SCID mice [33] . These antibodies occur late (mQnths 
to ~ears) a~ter B. burgdorferi infection, thus reflecting the long obser-
vation penod m our series. They may well have a protective func-
tion in chronic Lyme disease and thus account for the absence oflate 
complications in our patients. This point could be proved by deter-
• Frank E, Kim H, Casey R, Stover-Zipf J, Rass T: Lyme borrcliosis, 
chronic fatigue and hysteria (abstr). 4th International Conference on Lyme 
Borrcliosis, Stockholm, June 18-21, 1990. 
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mining the incidence of these antibodies in patients with primary 
neurologic manifestations. 
Our serologic data showed a high rate of seropositivity among the 
pat~ents (6~%) and the blood donor control group (31 %). Except for 
p.atl~nts With ACA. who proved 100% seropositive, no statistically 
slgmficant correlations ",:,ere fou~d between rositive B. burgdorferi 
serology (IgG) and clinical manifestation 0 borreliosis, interval 
between onset of symptoms and therapy, and time span since treat-
~ent and age of patients. Most important, no statistically significant 
differences w~re revealed between patients treated adequately and 
those treated madequately . The same was true for the four patients 
who had IgM antibodies against the recombinant flagella antigens 
used in the Virotech ELISA. 
The high prevalence of IgG antibodies in the ECM and LC 
groups with adequate treatment may be explained by tick bites after 
treatment. leading to seroconversiol1 at a later stage. This would be 
expected m an endemiC area, as documented by the high number of 
seropositive people in the blood donor group (see Table I). 
Fu~ther to t~1e high incidence of antibodies against the 29/31-kD 
protem mentioned above, some interesting conclusions can be 
~rawn from the immunoblot patterns observed. According to pub-
lished data, the number of antibodies against different proteins in-
cre~ses parallel to disease duration [10]. This was not observed in our 
senes; patients with antibodies against multiple proteins had not 
bee.n treated later than tho~e with antibodies to few proteins only. 
ThiS ~ay be seen as mdlcatlon of effective treatment; alternatively, 
as p01l1ted out by Szczepanski and Benach [43]' immunoblot pat-
terns may not be associated with specific clinical courses of the 
disease. 
. Antibodies against the 55/58-kD protein were the most common 
m both ser?positiv~ patients and blood donors. This is in seeming 
contrast With prevIOus studies [43,44] . Grodzicki and Steere [44] 
detected such antibodies in only eight of 30 patients . Most of these, 
however, were investigated at very short intervals after infection 
(1- 3 weeks), and the incidence of these antibodies increased with 
~ime, suggesting ~ coml?aratively late immune response. The long 
1I1terval between. 1I1f~ctlO.n a.nd treatment in many of our patients 
may eXjll~.m their 11lgh mCldence. The 58/60-kD protein of B. 
bur~do~en IS homologou~ to the 65-kD mycobacterial stress protein, 
:-vhlch IS capa~le ~f I11ducmg autoimmune phenomena such as exper-
Imental arthritiS m ratsJ45,46] . ~lthough no link to clinical symp-
toms ?ecame apparent 111 our patients, such highly conserved stress 
protems are candidates to act as immunogens in Lyme borreliosis 
and to provoke chronic disease. 
A~tibodies against the ~1-kD protein. have been reported as being 
restnct~d to early Lyme disease [23]; tlllS was clearly not the case in 
our patients. In endemic areas such as Austria, however, reinfection 
must be considered (60% of our patients reported tick bites after 
treat~ent). Antibodies against the 43/47-, 27-, 37-, and 66-kD 
p.rotems :were found more often in patients with cutaneous borrelio-
SIS ~han m the blood donor control group; in ACA, the antibodies 
agamst the 43/47-kD proteins were even present in 100%. The 
relevance. of these antibodies requires further investigation. 
The high prevalence .of AN~ in our patients was surprising. 
These were usually low tltered~ did not correlate with age or gender 
(compare [49]), and were mal111y of particulate pattern in Hep2 
cells. These f~a~ures ~o not suggest an incipient autoimmune disease 
or cross-~eactlvlty With B. burgdorferi antigens, which is mainly ob-
served With ~nti-DNA antibodies [48]. 
In conclUSIOn, our results suggest that late complications, particu-
larly of the nervou.s system and the joints, appear to be much less 
frequent after. pnmary cutaneous borreliosis than previously 
thought, even If treatment is performed inadequately or not at all. 
Of course: this ~nding does not suggest that therapy for dermato-
logiC manifestatIOns of Lyme borreliosis is unnecessary; it does sug-
gest, however, that the final outcome of this infection is influenced 
by ~ore fa~tors tha~ type and timing of the treatment of its primary 
manifestations, which appear to have little influence on the late 
Immune response and late complications. Furthermore, overdiag-
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nosis of extracutaneous symptoms seemingly relate to Lyme borre-
liosis should be avoided by application of more stringent diagnostic 
criteria. 
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